The authors describe a homogeneous, sensitive, and rapid bead-based sandwich immunoassay with a broad analytical range for quantifying insulin in human plasma. The assay was performed as a 2-step reaction by incubating the sample with a mixture of biotinylated anti-insulin antibody and beads covalently coated with anti-insulin antibody for 1 h. This was followed by incubation with beads covalently coated with streptavidin for 30 min. After the incubation steps, light generated from a chemiluminescent reaction within the beads was quantitated. The assay was run in 384-well plates with a sample volume of 5 µL. The analytical range extended from 1 to 10,000 pM. Intra-assay precision (% coefficient of variation) ranged from 1.9% to 3.8% for various insulin concentrations. Interassay precision ranged from 4.6% to 7.3%. Assay detection limit was 0.3 pM. There was no interference from moderate hemolysis (with hemoglobin up to 375 mg/dL), bilirubin (up to at least 50 mg/dL), triglyceride (up to at least 1000 mg/dL), biotin (up to at least 7.7 ng/mL), or ascorbic acid (up to 100 mg/dL). However, gross hemolysis did affect the assay. Comparable results were obtained for plasma (ethylenediamine tetra-acetic acid, citrate, and heparin treated) and serum. The correlation with enzyme-linked immunosorbent assay (ELISA) was good (y = 1.25x + 1.19, R 2 = 0.98). This method is convenient and represents an alternative to ELISA. (Journal of Biomolecular Screening 2007:240-247) 
INTRODUCTION
P HARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) studies are a crucial part of drug discovery and development. These studies require analysis of a high number of plasma and serum samples from animals and humans to measure concentrations of drugs and biomarkers. [1] [2] [3] [4] Demands to speed up the drug discovery process have resulted in increasing demands for assays that possess faster sample throughput for PK or PD studies in animal models in discovery and in clinical development stages.
There is at the same time a need for very sensitive assays and for reducing assay sample volumes to reduce the volume of blood to be drawn, especially in testing small animals such as rats and mice.
Insulin is a drug as well as a biomarker, and the insulin concentrations in a high number of samples have to be tested in relation to drug discovery. Furthermore, insulin concentrations may vary from very low and to very high. Insulin measurements thus require assays with high capacity, high sensitivity, and, at the same time, a broad analytical range.
Presently, insulin assays are frequently performed as enzymelinked immunosorbent assays (ELISAs) or radio immunoassays (RIAs) in discovery and clinical development stages. These assays require repeated wash cycles and large sample volumes and often do not have adequate sensitivity and working range.
Using high-throughput screening (HTS) technology and procedures seems to be an obvious answer to the capacity and effectiveness needs. The HTS approach will usually include assays that are homogenous, easy to automate, and robust in routine testing. Furthermore, these assays can be run in miniaturized formats. However, they also need to fulfill requirements of clinical biochemistry assays such as sensitivity, precision, and robustness to plasma interference.
Homogenous insulin sandwich immunoassays, such as FMAT 5 and HTRF, 6 have been described for serum and culture medium measurements. Heterogeneous assays with a built-in automated wash procedure, such as electrochemiluminescence (ECL), 7 the Gyrolab Bioaffi™ system, 8 and the Luminex system, 9 with many of the advantages of homogenous assays, have also been developed.
All these assays are easy to perform but have limited sensitivity (except for ECL), have a relatively long assay time, have a limited dynamic range, or do not allow manual assay set up in an open system.
In 1996, Ullman and others 10 showed that the luminescent oxygen channeling immunoassay (LOCI™) technology could be used for development of highly sensitive sandwich immunoassays (single tube) with a broad dynamic range. LOCI™ is a homogenous bead-based technology in which the proximity of 2 types of beads can lead to the emission of light through chemiluminescence. 11 Perkin Elmer (Boston, MA) has commercialized the LOCI™ technology for HTS (Alphascreen) and has shown that the assays can be performed in microplates and used for HTS.
Based on the LOCI™ technology and the Alphascreen HTS approach, we have further developed the technology to obtain sandwich immunoassays with the sensitivity and dynamic range described by Ullman and the capacity of the Alphascreen system from Perkin Elmer. This development has required the optimization of the sandwich assay to obtain the sensitivity and dynamic range needed as well as the robustness required to be handled in microplates. Furthermore, Perkin Elmer had to develop new acceptor beads containing Europium, new microplates with no cross-talk, and a fast plate reader.
Here we describe the performance of a 384-well plate-based LOCI™ sandwich immunoassay developed for measurement of insulin in human plasma. This assay illustrates the potential of the technology and the potential application of the technology for measurement of biomarkers and peptide and protein drugs in drug discovery.
MATERIALS AND METHODS

Samples
Human plasma and serum samples were obtained from healthy, adult volunteers, some of whom had fasted. Blood was collected in 10-mL Vacutainers (Becton Dickinson, Plymouth, UK). The tubes contained ethylenediamine tetra-acetic acid (EDTA), citrate, or heparin for plasma or no anticoagulant for serum. Samples were stored at -20°C.
Beads
Unconjugated Eu-acceptor beads (A beads) and streptavidincoated donor beads (SA-D beads) were from Perkin Elmer.
Antibodies
The monoclonal antihuman insulin antibodies HUI018 and OXI005 were from Novo Nordisk. The properties of these were described by Andersen and others. 12
Biotinylated antibody
OXI005 antibody was biotinylated according to standard procedures essentially as described 13 using Biotin-X-NHS (Merck, Darmstadt, Germany) in a phosphate-buffered saline (PBS) buffer at pH 7.2.
Coupling of antibody to beads
HUI018 antibody was coupled to A beads as described by the manufacturer except that the antibody was in 0.1 M phosphate (sodium), pH 8.0, and the amount of antibody used was 0.6 mg per mg beads. The resulting product is HUI018-A beads.
Assay plates
Low cross-talk 384-well Optiplates were from Perkin Elmer.
Calibration
Human insulin was from Novo Nordisk. Insulin-depleted human EDTA plasma pool was obtained by activated charcoal adsorption essentially as described. 14 Calibrators were prepared by dilution of insulin in the insulin-depleted human EDTA plasma.
The calibration data were fitted to a 4-parameter logistic function by weighted least-squares curve fitting. The squared errors in the fitting were weighted by the reciprocal of the variance at each concentration level. Data from previous measurements were used to estimate the variance. The highest concentration calibrator was given a higher weight to improve the curve fit at this concentration without significantly reducing the quality of the curve fit at other concentrations.
Assay procedure
The assay buffer contained 25 mM Hepes, 50 mM NaCl, 10 mM EDTA (tripotassium salt), 2 mg/mL Dextran T500 (Amersham Biosciences, Uppsala, Sweden), 0.5% bovine serum albumin (A-7888; Sigma-Aldrich, St. Louis, MO), 0.1% bovine gamma globulin (G-5009; Sigma-Aldrich), 0.2 mg/mL mouse immunoglobulin (HBR1; Scantibodies Laboratories, Santee, CA), 0.1% (w/v) Tween 20, 0.01% Proclin 300 (Sigma-Aldrich), and 0.01% gentamycin sulphate (Biological Industries, Israel) and was adjusted to pH 7.4.
The assay was performed in 384-well plates. The assay was run with calibrators and samples in duplicate, except as noted. The test sample and standards (5 µL) were added to the wells. Premixed HUI018-A beads and biotin OXI005 in assay buffer (15 µL) were added to the wells. The plates were covered with a lid and incubated at room temperature (RT) for 60 min. At the end of the incubation, SA-D beads in assay buffer (30 µL) were added. The plates were again covered with a lid and incubated for 30 min at RT, avoiding direct light because of the vulnerability of the D beads. Immediately thereafter, the plates were measured.
The final amounts and concentrations per well were as follows: sample 10%, HUI018-A beads 0.5 µg, biotin OXI005 4.5 nM, and SA-D beads 2.0 µg. The amount of biotin antibody was always lower than the capacity of the D beads.
The results were measured on an Envision Turbo Alpha (Perkin Elmer) with 1 detector, 70 ms excitation and 140 ms detection. The total processing time per 384-well plate was about 2.75 min, and the time for measuring from the 1st to the last well was about 2.33 min.
Interference
Interference testing was performed as previously described. 15 Interference was assessed by addition of the following interfering substances to EDTA plasma samples at the stated final concentrations: hemoglobin prepared from washed hemolysed erythrocytes, bilirubin (unconjugated) prepared in sodium carbonate/ dimethyl sulfoxide, triglyceride obtained in the form of Intralipid 20% fat emulsion from Fresenius Kabi (Uppsala, Sweden), biotin, and sodium ascorbate. Conditions were arranged such that the volume of added interfering substances was 5% of the total sample volume.
Comparison method
The insulin ELISA kit K6219 from Dako Cytomation (Copenhagen, Denmark) was used as the comparison method in this study. The assay was a traditional ELISA run in 96-well plates and with horseradish peroxidase/tetramethylbenzidine as the reporter system. It was built around the same antibodies as used in the LOCI™ assay (HUI018 and OXI005). The sample volume was 25 µL, and the detection limit of the assay was 5 pM (based on 3 SD), with a calibration range up to 1060 pM.
The assay was performed according to the manufacturer's instructions.
RESULTS
Kinetics
The LOCI™ assay was run as a 2-step assay.
Step 1 (sample + HUI018-A beads + biotin OXI005) reached steady state within 60 min of incubation.
Step 2 (SA-D beads added) was not run to equilibrium before reading. The assay worked well with a 10-min incubation in step 2. However, the reaction developed too fast compared to the Envision reading time for a 384-well plate; this resulted in a difference between the 1st and the last well of a plate measured. Step 2 was still developing after 30 min but slower; thus, the signal was not developing from the 1st to the last well. Incubation for 30 min in step 2 resulted in a slightly reduced sensitivity compared to a 10-min incubation time. However, the 30-min incubation was chosen because of the slower developing reaction. No significant change in signal and sensitivity was seen within the reading time for a 384-well plate on the Envision.
Calibration curve
A typical calibration curve for human insulin in insulindepleted human EDTA plasma is shown in Figure 1 .
A sigmoidal curve was obtained on a semilogarithmic plot with 11 concentrations including zero calibrator and with an intensity range between 700 and 1,300,000 cps from zero calibrator to the 10,000 pM calibrator (Fig. 1A) . The reproducibility was very good, as seen from the error bars, and the mean percentage coefficient of variation (CV%) for the calibration point signals was 3.7%. A linear plot of the low-concentration part of the assay is shown in Figure 1B . This plot gives a much clearer presentation of the signal increase within this part of the assay. It shows that there is a systematic increase in signal over the concentration range from 0 to 10 pM. This, combined with the low CV%s, makes it possible to discriminate between these low concentrations.
A calibration curve was run on each 384-well plate, and all samples on a plate were measured against the corresponding calibration curve.
Matrix effect
In Figure 2 , calibration curves made up in assay buffer and insulin-depleted plasma are illustrated. Insulin-depleted plasma has been shown to perform as untreated plasma (see recovery studies below). The results showed a marked effect of EDTA plasma on the assay compared to assay buffer. This means that calibrators have to be diluted in insulin-depleted plasma when analyzing plasma samples. These studies were done with a sample volume of 5 µL.
The comparability of results obtained in EDTA, citrate, and heparin plasma and serum derived from the same donors was investigated. Comparing matched samples of serum, EDTA, citrate, and heparin plasma from 11 volunteers in the EDTA plasma assay showed excellent agreement between the different specimen types (Figs. 3A-C) . This indicates that all the common types of blood sample material can be measured in the EDTA plasma assay.
Analytical range and sensitivity
The assay detection limit (LOD) was found to be 0.3 pM based on n = 12 and calculated from the mean of zero calibrator + 3 SD.
A dose-response curve was prepared by diluting insulin in insulin-depleted human plasma, including concentrations exceeding the upper calibrator. The calibration curve showed that a highdose hook effect was not seen at least up to a concentration of 50,000 pM (Fig. 4) . Thus, only at very high concentrations is there a risk of determining false low concentrations.
A precision profile given as the CV% for the concentration estimate as a function of the insulin concentration is shown in Figure 4 . The precision profile was constructed from back calculation of calibrators using the corresponding calibration curve run over 5 different days, thus giving the between-assay dose-precision profile. The precision profile shows that the precision is constant over a very broad concentration range. From these data, the mean recovery of insulin, that is, (determined concentration)/(expected concentration), for the calibrators was 102% (87%-118%) for the concentration range 1 to 10,000 pM.
The analytical range was set as the concentration range at which the interassay CV% of the determined insulin concentration was below 20% and the recovery was within the range of 80% to 120%. This gave a lower limit of quantification (LLOQ) of 1 pM. The assay covered a range of more than 4 orders of magnitude. From the precision profile in Figure 4 , it can be seen that from 1 pM and to 10,000 pM, the interassay CV%s are below 11%. The analytical range allowed for direct measurement of a broad range of concentrations, which only in rare cases will need test of samples at more than 1 dilution.
A total of 50 plasma samples were analyzed in an intra-assay study as described above, and a precision profile was constructed ( Fig. 5) . The variation was low; the mean CV% for all samples was 3.6%. Furthermore, it can be seen that samples from normal (including fasting) individuals have concentrations that fall comfortably within the range of the assay. The intraassay precision profile for plasma samples and the interassay precision profile from back calculation of calibrators are in good agreement.
Precision
Precision was assessed by performing a number of duplicate tests of each of 4 plasma samples with insulin concentrations in the range of 11.5 to 239 pM ( Table 1 ). In the intra-assay (withinassay, within-plate) study, 6 duplicates of each sample were analyzed in the same test and with each of the 6 duplicates placed randomly on the same plate. The intra-assay variation was calculated from the variation of the 6 determinations of insulin concentration. The intra-assay CV% was low, between 1.9% and 3.8%. In the interassay study (between plates, between runs), we assessed the variation by analyzing samples in the same manner in 5 tests, 1 duplicate per day, and each sample in a different position on the plate in each test. The interassay CV% was slightly higher, between 4.6% and 7.3%.
Analytical recovery
Six plasma samples containing from 38 pM to 264 pM insulin, respectively, were diluted with an insulin-depleted plasma pool (calibrator matrix).
The evaluations were done by calculating the ratio between the calculated and the expected values. The results with 2 of the plasma samples are shown in Table 2 . The recovery was 93% and 116% relative to the expected values showing complete parallelism. The results with the other 4 plasma samples were similar. This showed that the calibrator matrix was performing similar to plasma samples and that there was a linear relationship between the assay response and the sample volume.
Spiking recovery was assessed by adding a range of concentrations of insulin to 4 plasma samples with different insulin concentrations ranging from 14 to 236 pM.
The evaluations were done by calculating the ratio between measured and expected values. The results for 2 of the samples are shown in Table 3 . The percentage recovery of insulin was between 94% and 102%. The results with the other 2 plasma samples were similar, meaning that the recovery of insulin added to different plasma samples was quantitative, showing that the assay can accurately measure insulin in a real sample.
Interference
The effect of hemolysis, lipemia, and bilirubinemia and of the potentially interfering compounds biotin and ascorbic acid was assessed by adding hemolysate, bilirubin (unconjugated), Intralipid, biotin, and sodium ascorbate to normal human EDTA plasma samples with insulin concentrations in the range of 23 to 50 pM. The recoveries of insulin in these samples were calculated from insulin concentrations determined before and after addition of interfering substances. The results showed that hemolysis up to 375 mg/dL of hemoglobin, bilirubin up to at least 50 mg/dL, triglyceride up to at least 1000 mg/dL, biotin up to at least 7.7 ng/mL, and ascorbic acid up to 100 mg/dL did not reduce recovery below 80% ( Table 4 ). The same results were obtained with plasma samples with insulin concentrations between 77 and 127 pM (data not shown).
Heterophilic antibodies did not result in an agglutination of beads, thus not giving falsely elevated insulin concentrations (data not shown).
Comparison with ELISA
To further validate the assay, we analyzed plasma from 55 volunteers with insulin concentrations ranging from 9.4 to 239 pM in the LOCI™ assay and in an ELISA assay based on the same pair of antibodies (HUI018 and OXI005). The data presented include only values in natural samples. Regression analysis revealed good correlation between insulin determined in the 2 assays (Fig. 6A) . This is shown in more detail in Figure 6B , in which only 50 samples with insulin concentrations below 80 pM are included.
This comparison gives further evidence to the accuracy of the LOCI™ system. However, minor systematic differences were found with the ELISA, which gave slightly higher values than LOCI™.
A comparison of other assay parameters of ELISA and LOCI™ insulin assays are summarized in Table 5 , which shows LOCI™ to be superior with respect to key assay parameters.
DISCUSSION
In this study, we have established a 384-well plate-based homogeneous chemiluminescent sandwich immunoassay for human insulin suited for testing plasma/serum samples.
The 2-step format of the assay resulted in a faster and more sensitive assay. However, because the 2nd step had not reached The effect is expressed as recovery of insulin in the presence of interfering material compared to results in the absence of interfering substances. equilibrium, the incubation time of this step must be carefully controlled.
The ease of the homogenous plate-based format gives a very large test capacity. The assay can be handled as well manually as in automatic setup, which facilitates assay development and makes the technology more versatile.
The assay is very sensitive, with an LOD of 0.3 pM and an LLOQ of 1 pM, which allows measurement of very low concentrations of insulin. At these low signal levels, an assay is, of course, more prone to give false results because of interference. However, because the assay was found to be robust to plasma interference and not affected by autofluorescence (see below), the accuracy, even at these very low insulin concentrations, should be acceptable.
The broad analytical range of the assay will remove or reduce the need for testing samples at more than 1 concentration, often necessary with ELISA and RIA. This feature saves both time and resources.
Because the assay is a homogenous system, it is potentially more sensitive to plasma interference. Inner filter effects and singlet oxygen quenchers are the most prominent types of general interference for this type of assay. Problems with inner filter effects have been solved by using Eu in the acceptor beads emitting light at 614 nm, where inner filter effects are minimal in plasma. Potential singlet oxygen quenchers in plasma are ascorbic acid and heme iron. Furthermore, because the assay is based on a biotin-streptavidin interaction, free biotin may also affect the results. However, the LOCI™ assay was found to be refractory to plasma interference. The assay was unaffected by any of the interfering substances: hemoglobin (hemolysis), bilirubin, lipid, ascorbic acid, and biotin at concentrations that might be expected in a routine clinical laboratory setting. However, severe hemolysis will represent a practical problem when measuring in the LOCI™ assay. The assay was found to be robust to the effect of heterophilic antibodies because of the bovine gamma globulin and the mouse immunoglobulins, and this is expected to be the case with rheumatoid factor as well. Finally, because the LOCI™ emission wavelength is below the excitation wavelength (down conversion) and the measurements are performed in a timeresolved mode, the system is free of problems with sample autofluorescence.
The present insulin assay and an established commercially available ELISA based on the very same antibodies gave the same insulin concentration for a series of human plasma samples. This supports the idea that a LOCI™ assay can replace the ELISA. Comparison of different immunoassay technologies based on the same antibodies gives a very good basis for comparing the technologies. The LOCI™ assay was more sensitive than an ELISA 12 Heterogeneous Homogeneous ELISA = enzyme-linked immunosorbent assay; CV% = percentage coefficient of variation; LOD = assay detection limit. a. Mean of CV% for 3 samples covering the normal concentration range, n = 19 or 20. b. Mean of CV% for 4 samples covering the normal concentration range, n = 5 or 6. c. Calculated from zero calibrator + 3 SD. d. From LOD to upper calibrator. and 2 sandwich immunofluorometric assays, 16, 17 which were all based the on the 2 antibodies HUI018 and OXI005. The working range was similar for LOCI™ and the immunofluorometric assays, whereas it was smaller for the ELISA. Finally, LOCI™ is a mix-and-read assay, whereas the other assays require several washing steps. This makes the LOCI™ assay much easier to perform, gives a higher capacity, and makes it easier to automate. Thus, in many respects, the LOCI™ system is superior to ELISA and immunofluorometric assays. Comparison of the LOCI™ assay with some homogenous or homogenous-like insulin assays such as ECL (rat insulin in serum), 7 HTRF (rat insulin in medium), 6 Gyrolab (insulin-Asp in human serum), 8 Luminex (human insulin in human plasma), 9 and FMAT (rat insulin in rat plasma) 5 is more difficult because the antibodies, insulin, and sample types are different. Overall, the LOCI™ seems superior when considering a palette of important performance characteristics, such as sensitivity, analytical range, sample volume, assay time, and ease of handling. However, with respect to inner filter effects, the assays that include washing steps have an advantage, and neither of the other assays have problems with ascorbic acid.
The human insulin assay may be considered a model system for measuring drugs and biomarkers in biological samples. There is no reason to believe that it should not be possible to establish assays for other analytes and in other species and biological media. The technology thus lends itself for PK and PD studies and for testing biomarkers in culture medium.
In summary, we have described a new 384-well-based mixand-read high-throughput assay for the measurement of insulin in plasma and serum samples. This LOCI™ assay is a simple 2step assay that can be easily automated. It is sensitive, precise, and accurate with a broad analytical range. The assay demonstrates performance superior to classic ELISA. There is a lot to gain by replacing ELISA with LOCI™.
